We are fortunate to advise world-class, industry-leading companies, helping them tackle novel, complex issues and push the boundaries of technological progress. Our ability and confidence to go to trial is our core strength; our deep bench of experienced trial lawyers represents companies in their most significant matters, helping them protect their intellectual property and launch products. Our lawyers pair extensive experience in the courtroom and the boardroom with a thorough understanding of science and technology.

Steve Baughman Quoted in Bloomberg BNA Article on the Patent Process for Pharmaceutical Companies

March 16, 2018

Litigation partner Steve Baughman was quoted in a March 16 Bloomberg BNA article titled “Pharma Companies Could Hit Refresh on Patent Review Process.” Steve discussed some inherent limitations of the post-grant review (PGR) procedure, which allows a petitioner to claim that a patent is invalid for any reason. Commenting on the breadth of PGR estoppel, a legal construct where a determination in one proceeding bars a party from making those assertions in subsequent proceedings, Steve commented, “I believe this is likely to continue leading petitioners to consider PGRs only in fairly specific circumstances.”

» read the article

© 2019 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy